News|Articles|February 19, 2026
From Launch to Loss of Exclusivity: Reducing Access and Affordability Barriers Across the Brand Lifecycle
Author(s)CoverMyMeds
Access and affordability challenges continue to evolve across every phase of the biopharma brand lifecycle. Megan Wetzel, Vice President of Product, Access & Affordability at CoverMyMeds, shares actionable, lifecycle-specific approaches to removing barriers, easing provider burden, and supporting patient adherence. These strategies offer guidance for strengthening brand performance from launch through maturity while improving patient outcomes.
What you’ll learn:
- Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to address them proactively.
- Learn how data-driven insights and affordability solutions can help biopharma support providers and pharmacists at every stage.
- Understand the strategic role of lifecycle planning in improving medication access, reducing industry fragmentation and enhancing patient outcomes.
Trending on PharmExec
1
The Evolving Relationship Between FDA and Biotech
2
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
3
Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi
4
The Implications of GLP-1s Replacing Oncology as the Key Value Driver
5